[1]
Narayanan N, Rai R, Vaidya P, Desai A, Bhowmick T, Weinstein MP. Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia. Therapeutic advances in infectious disease. 2019 Jan-Dec:6():2049936119828964. doi: 10.1177/2049936119828964. Epub 2019 Feb 13
[PubMed PMID: 30792858]
Level 3 (low-level) evidence
[2]
Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs. 2001:61(4):525-51
[PubMed PMID: 11324682]
[3]
Yadav G, Thakuria B, Madan M, Agwan V, Pandey A. Linezolid and Vancomycin Resistant Enterococci: A Therapeutic Problem. Journal of clinical and diagnostic research : JCDR. 2017 Aug:11(8):GC07-GC11. doi: 10.7860/JCDR/2017/27260.10474. Epub 2017 Aug 1
[PubMed PMID: 28969155]
[4]
Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratalà J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Sep 1:63(5):e61-e111. doi: 10.1093/cid/ciw353. Epub 2016 Jul 14
[PubMed PMID: 27418577]
Level 1 (high-level) evidence
[5]
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. American journal of respiratory and critical care medicine. 2019 Oct 1:200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST. Epub
[PubMed PMID: 31573350]
Level 1 (high-level) evidence
[6]
Unni S, Siddiqui TJ, Bidaisee S. Reduced Susceptibility and Resistance to Vancomycin of Staphylococcus aureus: A Review of Global Incidence Patterns and Related Genetic Mechanisms. Cureus. 2021 Oct:13(10):e18925. doi: 10.7759/cureus.18925. Epub 2021 Oct 20
[PubMed PMID: 34812309]
[7]
Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014 Jul 15:59(2):147-59. doi: 10.1093/cid/ciu296. Epub 2014 Jun 18
[PubMed PMID: 24947530]
Level 1 (high-level) evidence
[8]
Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT, Rubinstein E, Holty JE, Messonnier NE, Smith TL, Pesik N, Treadwell TA, Bower WA, Workgroup on Anthrax Clinical Guidelines. Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerging infectious diseases. 2014 Feb:20(2):. doi: 10.3201/eid2002.130687. Epub
[PubMed PMID: 24447897]
[9]
Hamel JC, Stapert D, Moerman JK, Ford CW. Linezolid, critical characteristics. Infection. 2000 Jan:28(1):60-4
[PubMed PMID: 10697798]
[10]
Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy. 1998 May-Jun:18(3):456-62
[PubMed PMID: 9620097]
[12]
Antal EJ, Hendershot PE, Batts DH, Sheu WP, Hopkins NK, Donaldson KM. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. Journal of clinical pharmacology. 2001 May:41(5):552-62
[PubMed PMID: 11361052]
[13]
Besier S, Ludwig A, Zander J, Brade V, Wichelhaus TA. Linezolid resistance in Staphylococcus aureus: gene dosage effect, stability, fitness costs, and cross-resistances. Antimicrobial agents and chemotherapy. 2008 Apr:52(4):1570-2. doi: 10.1128/AAC.01098-07. Epub 2008 Jan 22
[PubMed PMID: 18212098]
[14]
Norrby R. Linezolid--a review of the first oxazolidinone. Expert opinion on pharmacotherapy. 2001 Feb:2(2):293-302
[PubMed PMID: 11336587]
Level 3 (low-level) evidence
[15]
Chen HA, Yang CJ, Tsai MS, Liao CH, Lee CH. Linezolid as salvage therapy for central nervous system infections due to methicillin-resistant Staphylococcus aureus at two medical centers in Taiwan. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi. 2020 Dec:53(6):909-915. doi: 10.1016/j.jmii.2020.08.004. Epub 2020 Aug 14
[PubMed PMID: 32859532]
[16]
Kempker RR, Heinrichs MT, Nikolaishvili K, Sabulua I, Bablishvili N, Gogishvili S, Avaliani Z, Little BP, Bernheim A, Derendorf H, Blumberg HM, Vashakidze S, Peloquin CA. A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis. The European respiratory journal. 2018 Feb:51(2):. doi: 10.1183/13993003.02166-2017. Epub 2018 Feb 7
[PubMed PMID: 29437945]
[17]
Dryden MS. Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. The Journal of antimicrobial chemotherapy. 2011 May:66 Suppl 4():iv7-iv15. doi: 10.1093/jac/dkr072. Epub
[PubMed PMID: 21521707]
[18]
Luque S, Muñoz-Bermudez R, Echeverría-Esnal D, Sorli L, Campillo N, Martínez-Casanova J, González-Colominas E, Álvarez-Lerma F, Horcajada JP, Grau S, Roberts JA. Linezolid Dosing in Patients With Liver Cirrhosis: Standard Dosing Risk Toxicity. Therapeutic drug monitoring. 2019 Dec:41(6):732-739. doi: 10.1097/FTD.0000000000000665. Epub
[PubMed PMID: 31259884]
[19]
Crass RL, Cojutti PG, Pai MP, Pea F. Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety. Antimicrobial agents and chemotherapy. 2019 Aug:63(8):. doi: 10.1128/AAC.00605-19. Epub 2019 Jul 25
[PubMed PMID: 31109977]
[21]
Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A Review of Antibiotic Use in Pregnancy. Pharmacotherapy. 2015 Nov:35(11):1052-62. doi: 10.1002/phar.1649. Epub
[PubMed PMID: 26598097]
[22]
Alene KA, Murray MB, van de Water BJ, Becerra MC, Atalell KA, Nicol MP, Clements ACA. Treatment Outcomes Among Pregnant Patients With Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis. JAMA network open. 2022 Jun 1:5(6):e2216527. doi: 10.1001/jamanetworkopen.2022.16527. Epub 2022 Jun 1
[PubMed PMID: 35687333]
Level 1 (high-level) evidence
[24]
Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2000 Jan:30(1):146-51
[PubMed PMID: 10619743]
[25]
Huang V, Gortney JS. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. Pharmacotherapy. 2006 Dec:26(12):1784-93
[PubMed PMID: 17125439]
[26]
Cantarini MV, Painter CJ, Gilmore EM, Bolger C, Watkins CL, Hughes AM. Effect of oral linezolid on the pressor response to intravenous tyramine. British journal of clinical pharmacology. 2004 Nov:58(5):470-5
[PubMed PMID: 15521893]
[27]
Sutton J, Stroup J, Som M. Linezolid-induced serotonin toxicity in a patient not taking monoamine oxidase inhibitors or serotonin receptor antagonists. Proceedings (Baylor University. Medical Center). 2016 Apr:29(2):214-5
[PubMed PMID: 27034576]
[28]
Curtis BR. Non-chemotherapy drug-induced neutropenia: key points to manage the challenges. Hematology. American Society of Hematology. Education Program. 2017 Dec 8:2017(1):187-193. doi: 10.1182/asheducation-2017.1.187. Epub
[PubMed PMID: 29222255]
[29]
Sharma S, Syal A, Gupta M, Tahlan A, Kaur B. Reversible Myelosuppresion With Prolonged Usage of Linezolid in Treatment of Methicillin-Resistant Staphylococcus aureus. Cureus. 2020 Oct 10:12(10):e10890. doi: 10.7759/cureus.10890. Epub 2020 Oct 10
[PubMed PMID: 33194459]
[30]
Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017 Feb 2:129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30
[PubMed PMID: 27903528]
Level 3 (low-level) evidence
[31]
Dilley M, Geng B. Immediate and Delayed Hypersensitivity Reactions to Antibiotics: Aminoglycosides, Clindamycin, Linezolid, and Metronidazole. Clinical reviews in allergy & immunology. 2022 Jun:62(3):463-475. doi: 10.1007/s12016-021-08878-x. Epub 2021 Dec 15
[PubMed PMID: 34910281]
[32]
Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, Leitch A, Loebinger MR, Milburn HJ, Nightingale M, Ormerod P, Shingadia D, Smith D, Whitehead N, Wilson R, Floto RA. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017 Nov:72(Suppl 2):ii1-ii64. doi: 10.1136/thoraxjnl-2017-210927. Epub
[PubMed PMID: 29054853]
[33]
Miller HV, Cao AA, McClelland CM, Lee MS. Linezolid optic neuropathy. Current opinion in ophthalmology. 2023 Nov 1:34(6):481-486. doi: 10.1097/ICU.0000000000000995. Epub 2023 Aug 21
[PubMed PMID: 37603423]
Level 3 (low-level) evidence
[34]
Elbarbry F, Moshirian N. Linezolid-associated serotonin toxicity: a systematic review. European journal of clinical pharmacology. 2023 Jul:79(7):875-883. doi: 10.1007/s00228-023-03500-9. Epub 2023 May 2
[PubMed PMID: 37129603]
Level 1 (high-level) evidence
[35]
Ioannou P, Stavroulaki M, Mavrikaki V, Papakitsou I, Panagiotakis S. A case of severe hyponatremia due to linezolid-induced SIADH. Journal of clinical pharmacy and therapeutics. 2018 Jun:43(3):434-436. doi: 10.1111/jcpt.12681. Epub 2018 Mar 14
[PubMed PMID: 29542179]
Level 3 (low-level) evidence
[36]
Dong QW, Tang L, Ge DD, Zhou TY, Zhao YC, Ma CH, Sun P. A case of linezolid-induced SIADH in elderly and a review of the literature. European review for medical and pharmacological sciences. 2022 Aug:26(16):5706-5709. doi: 10.26355/eurrev_202208_29505. Epub
[PubMed PMID: 36066143]
Level 3 (low-level) evidence
[37]
Garazzino S, Tovo PA. Clinical experience with linezolid in infants and children. The Journal of antimicrobial chemotherapy. 2011 May:66 Suppl 4():iv23-iv41. doi: 10.1093/jac/dkr074. Epub
[PubMed PMID: 21521704]
[38]
Wang RZ, Vashistha V, Kaur S, Houchens NW. Serotonin syndrome: Preventing, recognizing, and treating it. Cleveland Clinic journal of medicine. 2016 Nov:83(11):810-817. doi: 10.3949/ccjm.83a.15129. Epub
[PubMed PMID: 27824534]
[39]
Guillard P, de La Blanchardière A, Cattoir V, Fischer MO, Verdon R, Saint-Lorant G. Antimicrobial stewardship and linezolid. International journal of clinical pharmacy. 2014 Oct:36(5):1059-68. doi: 10.1007/s11096-014-9995-9. Epub 2014 Aug 19
[PubMed PMID: 25135806]
[40]
Barlam TF, Cosgrove SE, Abbo LM, MacDougall C, Schuetz AN, Septimus EJ, Srinivasan A, Dellit TH, Falck-Ytter YT, Fishman NO, Hamilton CW, Jenkins TC, Lipsett PA, Malani PN, May LS, Moran GJ, Neuhauser MM, Newland JG, Ohl CA, Samore MH, Seo SK, Trivedi KK. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 May 15:62(10):e51-77. doi: 10.1093/cid/ciw118. Epub 2016 Apr 13
[PubMed PMID: 27080992]